|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 17
Zeitschriftenartikel
Weiss, L.; Karthaus, M.; Riera-Knorrenschild, J.; Kretzschmar, A.; Welslau, M.; Vehling-Kaiser, U.; Pelz, H.; Ettrich, T. J.; Hess, J.; Reislaender, T.; Klein, A. und Heinemann, V
(2022):
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
In: Esmo Open, Bd. 7, Nr. 1
[PDF, 367kB]
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Modest, Dominik P.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C. B.; Holch, Julian W.; Einem, J. C. von; Held, S. und Heinemann, Volker
(2017):
Evaluation of survival across several treatment lines in
metastatic colorectal cancer: analysis of the FIRE-3 trial (AIO KRK0306).
In: European Journal of Cancer, Bd. 84: S. 262-269
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Hoster, Eva; Rosenwald, Andreas; Berger, F.; Bernd, Heinz Wolfram; Hartmann, S.; Loddenkemper, Christoph; Barth, Thomas E. F.; Brousse, N.; Pileri, S.; Rymkiewicz, G.; Kodet, Roman; Stilgenbauer, S.; Forstpointner, R.; Thieblemont, C.; Hallek, M.; Coiffier, B.; Vehling-Kaiser, U.; Bouabdallah, R.; Kanz, L.; Pfreundschuh, M.; Schmidt, C.; Ribrag, Vincent; Hiddemann, Wolfgang; Unterhalt, Michael; Kluin-Nelemans, J. C.; Hermine, Olivier; Dreyling, Martin und Klapper, Wolfram
(2016):
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
In: Journal of Clinical Oncology, Bd. 34, Nr. 12: S. 1386-1394
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Vehling-Kaiser, U.; Winkelmann, C.; Fischer von Weikersthal, L.; Clemens, M. R.; Gauler, T. C.; Marten, A.; Klein, S.; Kojouharoff, G.; Barner, M.; Geissler, M.; Greten, T. F.; Mansmann, Ulrich; Kirchner, T. und Heinemann, V.
(2013):
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
In: British Journal of Cancer BJC, Bd. 108, Nr. 2: S. 469-476
Kluin-Nelemans, H. C.; Hoster, Eva; Hermine, Olivier; Walewski, J.; Trneny, Marek; Geisler, C. H.; Stilgenbauer, S.; Thieblemont, C.; Vehling-Kaiser, U.; Doorduijn, J. K.; Coiffier, B.; Forstpointner, R.; Tilly, H.; Kanz, L.; Feugier, P.; Szymczyk, Michal; Hallek, M.; Kremers, S.; Lepeu, G.; Sanhes, L.; Zijlstra, J. M.; Bouabdallah, R.; Lugtenburg, P. J.; Macro, M.; Pfreundschuh, M.; Prochazka, V.; Di Raimondo, F.; Ribrag, Vincent; Uppenkamp, M.; Andre, M.; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2012):
Treatment of older patients with mantle-cell lymphoma.
In: New England Journal of Medicine / NEJM, Bd. 367, Nr. 6: S. 520-531
Laessig, D.; Stemmler, H. J.; Vehling-Kaiser, U.; Fasching, P. A.; Melchert, F.; Koelbl, H.; Stauch, M.; Maubach, P.; Scharl, A.; Morack, G.; Meerpohl, H.; Weber, B.; Kalischefski, B. und Heinemann, Volker
(2007):
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
In: Oncology, Nr. 5-6: S. 407-414
[PDF, 150kB]
Stemmler, J.; Mair, W.; Stauch, M.; Papke, J.; Deutsch, G.; Abenhardt, Wolfgang; Dorn, B.; Kentenich, C.; Malekmohammadi, M.; Jackisch, C.; Leinung, S.; Brudler, O.; Vehling-Kaiser, U.; Stamp, J. und Heinemann, Volker
(2005):
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
In: Oncology, Nr. 1: S. 71-78
[PDF, 158kB]